Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
36
AGIO Quote, Financials, Valuation and Earnings
Last price:
$29.19
Seasonality move
:
6.83%
Day range:
$27.10 - $30.04
52-week range:
$22.24 - $46.00
Dividend yield:
0%
P/E ratio:
3.91x
P/S ratio:
37.58x
P/B ratio:
1.33x
Volume:
915.7K
Avg. volume:
2.4M
1-year change:
-14.68%
Market cap:
$1.7B
Revenue:
$36.5M
EPS (TTM):
-$6.96
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AGIO
Agios Pharmaceuticals, Inc.
|
$10.6M | -$1.90 | 12.2% | -14.88% | $35.25 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
EYPT
EyePoint Plc
|
$3.3M | -$0.77 | -91.32% | -16.98% | $36.08 |
|
FULC
Fulcrum Therapeutics, Inc.
|
-- | -$0.29 | -100% | -0.03% | $19.00 |
|
MRNA
Moderna, Inc.
|
$869.9M | -$2.16 | -34.46% | -5.24% | $36.75 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AGIO
Agios Pharmaceuticals, Inc.
|
$29.19 | $35.25 | $1.7B | 3.91x | $0.00 | 0% | 37.58x |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
EYPT
EyePoint Plc
|
$18.26 | $36.08 | $1.5B | -- | $0.00 | 0% | 29.59x |
|
FULC
Fulcrum Therapeutics, Inc.
|
$12.01 | $19.00 | $650M | -- | $0.00 | 0% | -- |
|
MRNA
Moderna, Inc.
|
$32.75 | $36.75 | $12.8B | -- | $0.00 | 0% | 5.68x |
|
PFE
Pfizer Inc.
|
$25.03 | $28.62 | $142.3B | 14.59x | $0.43 | 6.87% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.35% | 3.272 | 1.9% | 12.81x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
EYPT
EyePoint Plc
|
10.41% | 2.852 | 2.35% | 6.81x |
|
FULC
Fulcrum Therapeutics, Inc.
|
3.41% | 3.715 | 1.41% | 17.25x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.934 | 7.28% | 3.30x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AGIO
Agios Pharmaceuticals, Inc.
|
$9.8M | -$116.9M | -26.57% | -27.53% | -907.37% | -$89.7M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
EYPT
EyePoint Plc
|
$245K | -$62M | -72.69% | -79.15% | -6420.81% | -$60.2M |
|
FULC
Fulcrum Therapeutics, Inc.
|
-$300K | -$21.9M | -30.08% | -31.15% | 65.62% | -$14.3M |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Agios Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns AGIO or CRMD?
CorMedix, Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of 49.9%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital AGIOAgios Pharmaceuticals, Inc.76.3% -$1.78 $1.3B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About AGIO or CRMD?
Agios Pharmaceuticals, Inc. has a consensus price target of $35.25, signalling upside risk potential of 30.64%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that CorMedix, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGIOAgios Pharmaceuticals, Inc.7 3 0 CRMDCorMedix, Inc.4 0 0 -
Is AGIO or CRMD More Risky?
Agios Pharmaceuticals, Inc. has a beta of 0.867, which suggesting that the stock is 13.282% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock AGIO or CRMD?
Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGIO or CRMD?
Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 37.58x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGIOAgios Pharmaceuticals, Inc.37.58x 3.91x $12.9M -$103.4M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns AGIO or EYPT?
EyePoint Plc has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of -6183.44%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat EyePoint Plc's return on equity of -79.15%.
Company Gross Margin Earnings Per Share Invested Capital AGIOAgios Pharmaceuticals, Inc.76.3% -$1.78 $1.3B EYPTEyePoint Plc25.36% -$0.85 $223.4M -
What do Analysts Say About AGIO or EYPT?
Agios Pharmaceuticals, Inc. has a consensus price target of $35.25, signalling upside risk potential of 30.64%. On the other hand EyePoint Plc has an analysts' consensus of $36.08 which suggests that it could grow by 97.61%. Given that EyePoint Plc has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe EyePoint Plc is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGIOAgios Pharmaceuticals, Inc.7 3 0 EYPTEyePoint Plc10 0 0 -
Is AGIO or EYPT More Risky?
Agios Pharmaceuticals, Inc. has a beta of 0.867, which suggesting that the stock is 13.282% less volatile than S&P 500. In comparison EyePoint Plc has a beta of 1.668, suggesting its more volatile than the S&P 500 by 66.808%.
-
Which is a Better Dividend Stock AGIO or EYPT?
Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. EyePoint Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGIO or EYPT?
Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are larger than EyePoint Plc quarterly revenues of $966K. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is lower than EyePoint Plc's net income of -$59.7M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while EyePoint Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 37.58x versus 29.59x for EyePoint Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGIOAgios Pharmaceuticals, Inc.37.58x 3.91x $12.9M -$103.4M EYPTEyePoint Plc29.59x -- $966K -$59.7M
-
Which has Higher Returns AGIO or FULC?
Fulcrum Therapeutics, Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of 69.26%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Fulcrum Therapeutics, Inc.'s return on equity of -31.15%.
Company Gross Margin Earnings Per Share Invested Capital AGIOAgios Pharmaceuticals, Inc.76.3% -$1.78 $1.3B FULCFulcrum Therapeutics, Inc.-- -$0.31 $205.4M -
What do Analysts Say About AGIO or FULC?
Agios Pharmaceuticals, Inc. has a consensus price target of $35.25, signalling upside risk potential of 30.64%. On the other hand Fulcrum Therapeutics, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 58.2%. Given that Fulcrum Therapeutics, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Fulcrum Therapeutics, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGIOAgios Pharmaceuticals, Inc.7 3 0 FULCFulcrum Therapeutics, Inc.6 1 0 -
Is AGIO or FULC More Risky?
Agios Pharmaceuticals, Inc. has a beta of 0.867, which suggesting that the stock is 13.282% less volatile than S&P 500. In comparison Fulcrum Therapeutics, Inc. has a beta of 3.172, suggesting its more volatile than the S&P 500 by 217.163%.
-
Which is a Better Dividend Stock AGIO or FULC?
Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fulcrum Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Fulcrum Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGIO or FULC?
Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are larger than Fulcrum Therapeutics, Inc. quarterly revenues of --. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is lower than Fulcrum Therapeutics, Inc.'s net income of -$19.6M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Fulcrum Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 37.58x versus -- for Fulcrum Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGIOAgios Pharmaceuticals, Inc.37.58x 3.91x $12.9M -$103.4M FULCFulcrum Therapeutics, Inc.-- -- -- -$19.6M
-
Which has Higher Returns AGIO or MRNA?
Moderna, Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of -19.69%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital AGIOAgios Pharmaceuticals, Inc.76.3% -$1.78 $1.3B MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About AGIO or MRNA?
Agios Pharmaceuticals, Inc. has a consensus price target of $35.25, signalling upside risk potential of 30.64%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 12.21%. Given that Agios Pharmaceuticals, Inc. has higher upside potential than Moderna, Inc., analysts believe Agios Pharmaceuticals, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGIOAgios Pharmaceuticals, Inc.7 3 0 MRNAModerna, Inc.3 16 1 -
Is AGIO or MRNA More Risky?
Agios Pharmaceuticals, Inc. has a beta of 0.867, which suggesting that the stock is 13.282% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.
-
Which is a Better Dividend Stock AGIO or MRNA?
Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGIO or MRNA?
Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is higher than Moderna, Inc.'s net income of -$200M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 37.58x versus 5.68x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGIOAgios Pharmaceuticals, Inc.37.58x 3.91x $12.9M -$103.4M MRNAModerna, Inc.5.68x -- $1B -$200M
-
Which has Higher Returns AGIO or PFE?
Pfizer Inc. has a net margin of -803.05% compared to Agios Pharmaceuticals, Inc.'s net margin of 21.32%. Agios Pharmaceuticals, Inc.'s return on equity of -27.53% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital AGIOAgios Pharmaceuticals, Inc.76.3% -$1.78 $1.3B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About AGIO or PFE?
Agios Pharmaceuticals, Inc. has a consensus price target of $35.25, signalling upside risk potential of 30.64%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Agios Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Agios Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings AGIOAgios Pharmaceuticals, Inc.7 3 0 PFEPfizer Inc.7 15 1 -
Is AGIO or PFE More Risky?
Agios Pharmaceuticals, Inc. has a beta of 0.867, which suggesting that the stock is 13.282% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock AGIO or PFE?
Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios AGIO or PFE?
Agios Pharmaceuticals, Inc. quarterly revenues are $12.9M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Agios Pharmaceuticals, Inc.'s net income of -$103.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 37.58x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGIOAgios Pharmaceuticals, Inc.37.58x 3.91x $12.9M -$103.4M PFEPfizer Inc.2.28x 14.59x $16.7B $3.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
